The McNamee factor which has been getting heaps of publicity since it's announcement on the 12th. IMO still a spec buy, same as most of these bio/medical small caps, if it falls back again after being current 'flavor of the month', with McNamee involved, I'll take a punt, but as he says about DHA emulsion — aka omega 3 fish oil — to treat premature infants with bronco-pulmonary dysplasia (BPD): “It’s a binary outcome, It either improves infant health or not.’’ "Investors will know whether they are in Clover when the trial results are reported in the second quarter of 2016. Spec buy".
Link: Australian Article
Link: Clover: Enters Medical Alliance
Potential, page-7
Add CLV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
-0.005(1.01%) |
Mkt cap ! $60.11M | |||
| Open | High | Low | Value | Volume |
| 49.0¢ | 49.5¢ | 49.0¢ | $8.983K | 18.23K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32789 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 44797 | 1 |
View Market Depth
| Last trade - 15.45pm 15/11/2024 (20 minute delay) ? |
| CLV (ASX) Chart |
